Q4 total revenue of $4.8 million, up 18% over the prior year
Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insurance authorizations received in Q4, up 87% over the prior year
Record backlog of 230 patients as of December 31, 2023
Introduces 2024 first quarter and full year guidance
Conference call begins at 4:30 p.m. Eastern time today
BOSTON (March 7, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2023. Read more.